Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : GlaxoSmithKline Research & Development
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
An Open Label Continuation Study of the Oral AKT Inhibitor GSK2110183 in Subjects with Solid Tumors and Hematologic Malignancies
The primary objective of the study is to provide treatment with afuresertib for subjects who have previously participated in an afuresertib study sponsored by GSK or another research organization work...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
Effect of Otelixizumab in New-Onset Type 1 Diabetes Mellitus (NOT1DM)
To assess the effect of a single course of otelixizumab treatment on the acute and long term safety and tolerability of otelixizumab in NOT1DM patients.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
Albiglutide versus Placebo in New-Onset Type 1 Diabetes Mellitus
• Determine the effect of albiglutide therapy versus placebo on endogenous insulin secretion over 52 weeks when added to standard of care in subjects with new onset type 1 diabetes mellitus (NOT1DM)
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 4 ans
Efficacy study to evaluate fluticasone furoate /vilanterol Inhalation Powder delivered once daily via the Dry Powder Inhaler Ellipta™ compared with usual ICS/LABA maintenance therapy delivered by Dry Powder Inhaler in subjects with Persistent Asthma
• The primary objective of the study is to compare the efficacy of FF/VI 92mcg/ 22mcg or FF/VI 184mcg/22mcg with usual fixed combinations ICS/LABA for asthma maintenance therapy at Week 12 (Visit 4).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
A randomised, double-blind, placebo-controlled, Bayesian adaptive dose finding study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat intravenous infusions GSK315234A in patients with active rheumatoid arthritis (RA)
To assess: 1) safety and tolerability of GSK315234A after single and repeat i.v. infusions in subjects with active RA on background of methotrexate (MTX). 2) effect of GSK315234A on disease activity ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
A safety study for subjects with severe asthma who participated in MEA115575 or MEA115588
To describe the safety profile of mepolizumab in subjects receiving long-term treatment
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
A 28-Day, Polysomnographic and Subjective Assessment of Vestipitant (15mg/day) for the Treatment of Primary Insomnia in Adult Outpatients
• To compare the efficacy of oral vestipitant (15mg/day) with placebo after 4 weeks of nightly treatment in adult outpatients diagnosed with primary insomnia, as determined objectively by polysomnogra...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 4 ans
A 19-week, randomized, double-blind, placebo-controlled, three-period, cross-over pilot study comparing the effect of salmeterol/fluticasone propionate 50/100mcg BID, fluticasone propionate 100mcg BID and placebo on peripheral blood eosinophils and serum IL-5 in response to allergen challenge in asthma subjects
To investigate whether regular treatment with salmeterol in combination with fluticasone propionate (FP) has an effect on blood markers of airway inflammation compared with FP alone or placebo in resp...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 4 ans
An open label, repeat dose, dose escalation study conducted in RLS patients to characterize pharmacokinetics and food effect of ropinirole controlled release for RLS
• To determine the effect of food on absorption of ropinirole CR-RLS at 6mg (highest tablet strength) • To demonstrate the dose proportionality for ropinirole CR-RLS over the dose range 1-6mg • To det...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
A randomized, parallel group study to evaluate the effect of Umeclidinium (UMEC) added to Inhaled corticosteroid/ long-acting beta-agonist combination therapy in subjects with Chronic Obstructive Pulmonary Disease COPD
The primary objective is to evaluate the efficacy and safety of the addition of UMEC 62.5mcg once-daily to ICS/LABA therapy, compared with placebo once-daily plus ICS/LABA therapy over 12 weeks in sub...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
6
7
8
9
10
11
12
13
14
15
Suivant